D2A21

Drug Profile

D2A21

Alternative Names: D2A21 gel - Demegen; Demegel; Peptidyl MIM; Provena

Latest Information Update: 13 Jul 2017

Price : $50

At a glance

  • Originator Demegen
  • Developer Demegen; DFB Pharmaceuticals
  • Class Antibacterials; Antineoplastics; Peptide antibiotics
  • Mechanism of Action Apoptosis stimulants; Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Burn infections
  • Preclinical Bacterial infections
  • Discontinued Cancer; Protozoan infections

Most Recent Events

  • 13 Jul 2017 D2A21 is still in Preclinical trials for Bacterial infections in USA (Demegen pipeline, July 2017)
  • 13 Jul 2017 Phase-III clinical trials in Burn infections in USA (Topical) before July 2017 (Demegen pipeline, July 2017)
  • 27 Jun 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top